Strengthening our Advisory Board with addition of Mark McKenna as Strategic Advisor and Peter Libby, MD as a Clinical AdvisorExpanding the Phase 2 recurrent pericarditis study into Canada, EU and the UK to evaluate QD dose ranging in preparation for the global Phase 3 development planInterim analysis for the ongoing Phase 2 recurrent pericarditis study to now be presented as part of Ventyx’s R&D Day planned for Q1 2026 SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ve ...

Core Viewpoint - RBC Capital Markets upgraded Neumora Therapeutics, Inc. from Sector Perform to Outperform, raising the price forecast from $4 to $7, indicating a positive outlook on the company's evolving pipeline beyond neurology [1] Group 1: Company Developments - Neumora is positioning itself with a competitive early asset in the NLRP3 class, showing promise in large-market indications such as obesity and cardiometabolic disease [1] - The company plans to initiate a clinical program with NMRA-215 in Q1 2026, with 12-week human proof-of-concept data expected in the same year [3] - Neumora's M4 franchise includes NMRA-861 and NMRA-898, which may provide improved therapeutic profiles for schizophrenia and other neuropsychiatric disorders [3] Group 2: Financial Position - Neumora has $171.5 million in cash, cash equivalents, and marketable securities, which is expected to support operations into 2027 [5] Group 3: Market Potential - The NLRP3 target is emerging as significant for metabolic and obesity treatments, with Neumora potentially becoming a contender in this space [5] - Early data suggests broad utility for NLRP3 inhibitors in various conditions, including obesity and neuroinflammation, with no significant safety issues reported [6] Group 4: Stock Performance - NMRA stock increased by 6.92% to $2.395 as of the last check on Monday [7]

Core Insights - Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases [8] Pipeline Updates and Anticipated Milestones - Ventyx is advancing two novel NLRP3 inhibitors, VTX3232 and VTX2735, through Phase 2 trials targeting neurodegenerative, cardiovascular, and metabolic diseases [2] - The Phase 2 biomarker trial for VTX3232 in Parkinson's disease is expected to complete in Q2 2025, with key endpoints including safety and pharmacokinetics [3] - Results from the Phase 2 trial of VTX3232 in obesity and cardiometabolic risk factors, as well as VTX2735 in recurrent pericarditis, are anticipated in the second half of 2025 [3][4] Financial Overview - As of March 31, 2025, Ventyx reported cash, cash equivalents, and marketable securities of $228.8 million, sufficient to fund operations into at least H2 2026 [11][17] - Research and Development (R&D) expenses for Q1 2025 were $22.9 million, down from $33.7 million in Q1 2024 [11] - General and Administrative (G&A) expenses decreased to $7.2 million in Q1 2025 from $8.0 million in Q1 2024 [11] - The net loss for Q1 2025 was $27.4 million, compared to a net loss of $38.6 million in Q1 2024 [11][15] Inflammatory Bowel Disease (IBD) Portfolio - Ventyx's IBD portfolio includes two Phase 2 compounds: tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor [9] - Tamuzimod has shown robust clinical and endoscopic remission rates compared to placebo, positioning it as a potential backbone for future combination therapies in ulcerative colitis [11] - VTX958 demonstrated a dose-dependent endoscopic response in Crohn's disease, suggesting potential disease-modifying benefits [11]